Oral antihyperglycemic therapy for type 2 diabetes mellitus

Cheng, Alice Y. Y.; Fantus, I. George
January 2005
CMAJ: Canadian Medical Association Journal;1/18/2005, Vol. 172 Issue 2, p213
Academic Journal
DIABETES MELLITUS IS A CHRONIC DISEASE that is growing in prevalence worldwide. Pharmacologic therapy is often necessary to achieve optimal glycemic control in the management of diabetes. Orally administered antihyperglycemic agents (OHAs) can be used either alone or in combination with other OHAs or insulin. The number of available OHAs has increased significantly in the last decade, which translates into more therapeutic options and complex decision-making for physicians. This review article is designed to help with these decisions. We review the mechanism of action, efficacy and side effects of the different classes of OHAs action, efficacy and side effects of the different classes of OHAs...


Related Articles

  • Converting Patients with Type 2 Diabetes to Insulin. Walling, Anne D. // American Family Physician;2/15/2004, Vol. 69 Issue 4, p952 

    Discusses research being done on the importance of addressing patients' concerns and medical issues involved in initiating insulin therapy. Reference to a study by M. McIntyre et al published in the July 2003 issue of the journal "Practitioner"; Hyperglycemic symptoms in type-2 diabetic...

  • Refining Treatment of Type 2 Diabetes. Padilla, Alfred J. // Cortlandt Forum;09/25/99, Vol. 12 Issue 9, p168 

    Presents an overview of treatments of type 2 diabetes. Three factors that contribute to the hyperglycemia of type 2 diabetes; Disruption of insulin secretion in type 2 diabetes; Five classes of oral agents available for the treatment of patients. INSETS: Case 1: A Reversible Diabetogenic...

  • Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus. Stolar, Mark W. // Mayo Clinic Proceedings;Dec2010 Supplement, Vol. 85, pS50 

    Traditionally, successful treatment of patients with type 2 diabetes mellitus (DM) has been defined strictly by achievement of targeted glycemic control, primarily using a stepped-care approach that begins with changes in lifestyle combined with oral therapy that is slowly intensified as disease...

  • Got the Combination? JSR; Harrar, Sari // Prevention;Mar2003, Vol. 55 Issue 3, p180 

    The Avandamet pill for type 2 diabetes combines two medications that help maintain lower blood sugar levels throughout the day, without the peaks and periods of high blood sugar that raise your risk for complications. Avandamet combines rosiglitazone (Avandia), a drug that makes cells more...

  • Polypharmacy as a Risk Factor in the Treatment of Type 2 Diabetes. Austin, Roger P. // Diabetes Spectrum;Winter2006, Vol. 19 Issue 1, p13 

    The article discusses the risk factors associated with polypharmacy, the concurrent use of multiple medications in the same patient, in the treatment of type 2 diabetes. It explains why polypharmacy is inevitable when treating a common chronic condition. It offers information on the predictor of...

  • Using Individualized Predictive Disease Modeling to Identify Patients with the Potential to Benefit from a Disease Management Program for Diabetes Mellitus. Weber, Christian; Neeser, Kurt // Disease Management;Aug2006, Vol. 9 Issue 4, p242 

    Diabetes is an increasing health problem, but efforts to handle this pandemic by disease management programs (DMP) have shown conflicting results. Our hypothesis is that, in addition to a program's content and setting, the choice of the right patients is crucial to a program's efficacy and...

  • Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Zonszein, Joel; Groop, Per-Henrik // Diabetes Therapy;Dec2016, Vol. 7 Issue 4, p621 

    Introduction: The duration of uncontrolled type 2 diabetes mellitus (T2DM) can adversely impact small and large vessels, eventually leading to microvascular and macrovascular complications. Failure of therapeutic lifestyle changes, monotherapy, and clinical inertia contribute to persistent...

  • Microvascular and Macrovascular Complications of Diabetes Mellitus. King, Keecia D.; Jones, Jocelyn D.; Warthen, Jessica // American Journal of Pharmaceutical Education;Dec2005, Vol. 69 Issue 5, p1 

    Approximately 7 out of every 10 of the 1.7 million Americans who die each year die of a chronic disease such as diabetes mellitus. Hyperglycemia may lead to diabetic complications causing damaging effects to the kidneys, nervous system, ocular function, cardiovascular system, and circulatory...

  • Extrinsic Factors Involved in the Differentiation of Stem Cells into Insulin-Producing Cells: An Overview. Wong, Rebecca S. Y. // Experimental Diabetes Research;2011, Special section p1 

    Diabetes mellitus is a chronic disease with many debilitating complications. Treatment of diabetes mellitus mainly revolves around conventional oral hypoglycaemic agents and insulin replacement therapy. Recently, scientists have turned their attention to the generation of insulin-producing cells...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics